Arylkylamine spirofuropyridines useful in therapy

US6995167B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• James Loch · Watertown, US
• George B. Mullen · Avon, US
• Eifion Phillips · Boothwyn, US

Key dates

• Filing date: Dec 23, 1999
• Grant date: Feb 7, 2006
• Expiry date: Dec 23, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of formula I, wherein NRR1 is attached at the 5- or 6-position of the furopyridine ring; R is hydrogen, C1–C4 alkyl, or COR2; R1 is (CH2)nAr, CH2CH═CHAr, or CH2C≡CAr; n is 0 to 3; A is N or NO; Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur, any of which may optionally be substituted with one to two substitutents independently selected from: halogen, trifluoromethyl, or C1–C4 alkyl; R2 is hydrogen, C1–C4 alkyl, C1–C4 alkoxy or phenyl ring optionally substituted with one to three of the following substituents: halogen, C1–C4 alkyl, C2–C4 alkenyl, C2–C4 alkynyl, OH; OC1–C4 alkyl, CO2R5, —CN, —NO2, —NR3R4, or —CF3; R3, R4 and R5 may be hydrogen, C1–C4 alkyl, or phenyl ring optionally substituted with one to three of the following substituents: halogen, C1–C4 alkyl, C2–C4 alkenyl, C2–C4 alkynyl, OH; OC1–C4 alkyl, —CN, —NO2, or —CF3; and enantiomers thereof, and pharmaceutically acceptable salts thereof, proc…